Open AccessRifabutin Is Active against Mycobacterium abscessus in Mice
Author(s) -
Thomas Dick,
Sung Jae Shin,
Won Jung Koh,
Véronique Dartois,
Martin Gengenbacher
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01943-19
Subject(s) - rifabutin , rifamycin , mycobacterium abscessus , clarithromycin , medicine , nontuberculous mycobacteria , mycobacterium tuberculosis , microbiology and biotechnology , antibiotics , antibacterial agent , mycobacterium , tuberculosis , immunology , biology , pathology
There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc scid /NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.